Search

Memorial Sloan Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.

… Tuesday, August 27, 2013 Memorial Sloan Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features such as embargoed content for registered users and “trending topics” – a continually updated listing of story ideas and available experts to comment on the latest health

Learn about how our donor community is funding life-changing cancer research at Memorial Sloan Kettering and ensuring a brighter future for people with cancer around the world.

… Friday, January 1, 2021 Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center is essential to advancing our mission. Read more to learn about your impact in 2021. Fundraising Events at MSK Fred’s Team Participants raised more than $7.3 million in 2021

RSV is a respiratory disease that spreads in the fall and winter months. Learn about the RSV vaccines, which are approved for people ages 50 and older.

… Friday, September 13, 2024 People ages 50 to 74 who are at risk for getting very sick from RSV can get vaccinated, after talking with their doctor. People ages 75 and older should get an RSV vaccine. Mini Kamboj Mini Kamboj Mini Kamboj has answers to some frequently asked questions about the RSV vaccines

Memorial Sloan Kettering and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop a unique monoclonal antibody.

… Tuesday, January 28, 2014 Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform

An immunotherapy drug might be an effective initial treatment for people with metastatic Merkel cell carcinoma.

… Thursday, March 22, 2018 Summary Merkel cell carcinoma  is hard to treat after it has spread. A new immunotherapy drug, avelumab, was recently approved by the FDA for people with metastatic Merkel cell carcinoma who had previously received chemotherapy. Now new research suggests avelumab could be even

Learn about lung cancer in women, the links between lung cancer and smoking, the relationship between lung cancer and genetics, and the benefits of being treated at a hospital that offers many clinical trials for lung cancer.

… Friday, January 17, 2025 According to the latest statistics from the American Cancer Society, incidence rates of lung cancer are now higher in women than in men among people younger than 65 years.  Overall, though, the news about lung cancer is largely hopeful. In fact, a 2023 study  from the American

Infórmese sobre el cáncer pulmonar en mujeres, la conexión entre el cáncer pulmonar y el tabaquismo, la relación entre el cáncer pulmonar y la genética, y los beneficios de recibir tratamiento en un hospital que ofrece numerosos ensayos clínicos para el cáncer pulmonar.

… Friday, January 17, 2025 Según las estadísticas más recientes de la Sociedad Americana contra el Cáncer, las tasas de incidencia de cáncer pulmonar son ahora más altas en mujeres que en hombres entre las personas menores de 65 años.  Sin embargo, en general, las noticias sobre el cáncer pulmonar son

Learn the most frequently asked questions about immunotherapy, a form of cancer treatment that uses the body's own immune system to overpower cancer cells. Learn who it can help, how it works, and how experts at MSK are finding ways to make it benefit more people, including new combinations with other cancer treatments like chemotherapy, surgery, radiation and more.

… Tuesday, November 7, 2023 Immunotherapy is one of the most promising approaches to cancer treatment . Unlike other forms of cancer treatment, in which drugs or radiation target cancer cells directly, immunotherapy targets your immune system, boosting its innate power to fight the cancer. But how does

After receiving a stem cell transplant for multiple myeloma, John Savarese developed graft-versus-host disease (GVHD). MSK’s specialized GVHD clinic got him back to feeling like himself again.

… Thursday, April 7, 2022 When John Savarese went to see Memorial Sloan Kettering Cancer Center (MSK) hematologic oncologist Doris Ponce for the first time in the fall of 2021, he was not well. “I felt like I was 100 years old,” says the 63-year-old retired air traffic controller and Brooklyn native. “

MSK experts acted quickly to understand the possible effects of COVID-19 on cancer patients and drew on vast experience to explore new treatments.

… Thursday, October 1, 2020 In March 2020, medical oncologist Santosha Vardhana was faced with a new challenge: Many of his patients with lymphoma were becoming infected with the COVID-19 virus. As he saw more cases, Dr. Vardhana noticed a troubling pattern begin to emerge. Patients were managing well